接受艾美赛珠单抗预防治疗的血友病A患者手术结局:HAVEN 1-4研究经验
汇总HAVEN 1-4三项3期试验中接受艾美赛珠单抗预防治疗的血友病A患者共233例手术(215例小手术、18例大手术)。215例小手术中141例(65.6%)未额外使用凝血因子浓缩物,其中121例(85.8%)无术后出血;18例大手术中15例(83.3%)加用预防性凝血因子浓缩物,其中12例(80.0%)无术中或术后出血。数据表明接受艾美赛珠单抗预防治疗的血友病A患者可安全进行小手术和大手术。
要点
- 215例小手术中141例(65.6%)未额外使用预防性凝血因子浓缩物,其中121例(85.8%)无术后出血。
- 18例大手术中15例(83.3%)加用预防性凝血因子浓缩物,其中12例(80.0%)无术中或术后出血。
- 233例手术中215例为小手术(含小牙科及关节操作、中心静脉通路装置置入或移除、内镜检查),18例为大手术(含关节置换术和滑膜切除术)。
核心结论
- 数据表明接受艾美赛珠单抗预防治疗的血友病A患者可安全进行小手术和大手术。
研究设计与样本
- 汇总HAVEN 1-4三项3期临床试验数据,纳入接受艾美赛珠单抗预防治疗的血友病A患者(伴或不伴FVIII抑制物)的所有小手术和大手术。
- 共233例手术:215例小手术来自115例血友病A患者(64例伴FVIII抑制物),18例大手术来自18例血友病A患者(10例伴FVIII抑制物)。
- 围手术期止血支持由治疗医生酌情决定。
- 总体中位(IQR)年龄33.5(13.0-49.0)岁,手术前中位(IQR)艾美赛珠单抗暴露时间278.0(177.0-431.0)天。
主要发现
- 215例小手术中141例(65.6%)未额外使用预防性凝血因子浓缩物,其中121例(85.8%)无术后出血。
- 18例大手术中15例(83.3%)加用预防性凝血因子浓缩物,其中12例(80.0%)无术中或术后出血。
局限性
- 原文未报告局限性
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Many people with hemophilia A (PwHA) undergo surgery in their lifetime, often because of complications of their disease. Emicizumab is the first bispecific monoclonal antibody prophylactic therapy for PwHA, and its efficacy and safety have been previously demonstrated; however, there is a need to build an evidence base on the management of PwHA on emicizumab undergoing surgery. Data from the HAVEN 1-4 phase 3 clinical trials were pooled to provide a summary of all minor and major surgeries in PwHA with or without factor VIII (FVIII) inhibitors who were receiving emicizumab prophylaxis. Overall, 233 surgeries were carried out during the HAVEN 1-4 trials: 215 minor surgeries (including minor dental and joint procedures, central venous access device placement or removal, and endoscopies) in 115 PwHA (64 with FVIII inhibitors) and 18 major surgeries (including arthroplasty and synovectomy) in 18 PwHA (10 with FVIII inhibitors). Perioperative hemostatic support was at the discretion of the treating physician. Overall, the median (interquartile range [IQR]) age was 33.5 (13.0-49.0) years and the median (IQR) emicizumab exposure time before surgery was 278.0 (177.0-431.0) days. Among the 215 minor surgeries, 141 (65.6%) were managed without additional prophylactic factor concentrate, and of those, 121 (85.8%) were not associated with a postoperative bleed. The majority (15 of 18 [83.3%]) of major surgeries were managed with additional prophylactic factor concentrate. Twelve (80.0%) of these 15 surgeries were associated with no intraoperative or postoperative bleeds. The data demonstrate that minor and major surgeries can be performed safely in PwHA receiving emicizumab prophylaxis. These trials are registered at www.clinicaltrials.gov as #NCT02622321, #NCT02795767, #NCT02847637, and #NCT03020160.
引用
- Kruse-Jarres R, Peyvandi F, Oldenburg J, et al. Surgical outcomes in people with hemophilia A taking emicizumab prophylaxis: experience from the HAVEN 1-4 studies. Blood Adv. 2022. PMID: 35939785. doi:10.1182/bloodadvances.2022007458
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。